<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37563241</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Daratumumab monotherapy for refractory lupus nephritis.</ArticleTitle><Pagination><StartPage>2041</StartPage><EndPage>2047</EndPage><MedlinePgn>2041-2047</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-023-02479-1</ELocationID><Abstract><AbstractText>Treatment-refractory lupus nephritis (LN) has a high risk of a poor outcome and is often life-threatening. Here we report a case series of six patients (one male and five females) with a median age of 41.3&#x2009;years (range, 20-61&#x2009;years) with refractory LN who received renal biopsies and were subsequently treated with intravenous daratumumab, an anti-CD38 monoclonal antibody (weekly for 8&#x2009;weeks, followed by eight biweekly infusions and up to eight monthly infusions). One patient did not show any improvement after 6&#x2009;months of therapy, and daratumumab was discontinued. In five patients, the mean disease activity, as assessed by the Systemic Lupus Erythematosus Disease Activity 2000 index, decreased from 10.8 before treatment to 3.6 at 12&#x2009;months after treatment. Mean proteinuria (5.6&#x2009;g per 24&#x2009;h to 0.8&#x2009;g per 24&#x2009;h) and mean serum creatinine (2.3&#x2009;mg&#x2009;dl<sup>-1</sup> to 1.5&#x2009;mg&#x2009;dl<sup>-1</sup>) also decreased after 12&#x2009;months. Improvement of clinical symptoms was accompanied by seroconversion of anti-double-stranded DNA antibodies; decreases in median interferon-gamma levels, B cell maturation antigen and soluble CD163 levels; and increases in C4 and interleukin-10 levels. These data suggest that daratumumab monotherapy warrants further exploration as a potential treatment for refractory LN.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Roccatello</LastName><ForeName>Dario</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4419-6813</Identifier><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy. dario.roccatello@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fenoglio</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caniggia</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamgaing</LastName><ForeName>Joelle</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naretto</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecchi</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubini</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Simone</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Vecchio</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cozzi</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciascia</LastName><ForeName>Savino</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1266-9441</Identifier><AffiliationInfo><Affiliation>University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Citt&#xe0; di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>4Z63YK6E0E</RegistryNumber><NameOfSubstance UI="C556306">daratumumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors received no specific funding for this work. The authors declare no conflicts of interest and declare no support from any organizations for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3&#x2009;years; and no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37563241</ArticleId><ArticleId IdType="pmc">PMC10427415</ArticleId><ArticleId IdType="doi">10.1038/s41591-023-02479-1</ArticleId><ArticleId IdType="pii">10.1038/s41591-023-02479-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaul A, et al. Systemic lupus erythematosus. Nat. Rev. Dis. Prim. 2016;2:16039. doi: 10.1038/nrdp.2016.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, Sciascia S, Rossi D, Fenoglio R. Refractory systemic lupus erythematosus: identification and pharmacological management. Drugs. 2023;83:117&#x2013;134. doi: 10.1007/s40265-022-01824-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01824-x</ArticleId><ArticleId IdType="pubmed">36729344</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee CS, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann. Rheum. Dis. 2004;63:525&#x2013;529. doi: 10.1136/ard.2002.003574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2002.003574</ArticleId><ArticleId IdType="pmc">PMC1755006</ArticleId><ArticleId IdType="pubmed">15082482</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, III, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 1986;314:614&#x2013;619. doi: 10.1056/NEJM198603063141004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198603063141004</ArticleId><ArticleId IdType="pubmed">3511372</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013;22:1135&#x2013;1141. doi: 10.1177/0961203313502864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313502864</ArticleId><ArticleId IdType="pubmed">23995863</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhelm T, et al. Clinical experience of proteasome inhibitor bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: a nationwide study. Front. Immunol. 2021;12:756941. doi: 10.3389/fimmu.2021.756941.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.756941</ArticleId><ArticleId IdType="pmc">PMC8517506</ArticleId><ArticleId IdType="pubmed">34659263</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo CY, et al. Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus. Apher. Sci. 2010;43:335&#x2013;340. doi: 10.1016/j.transci.2010.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2010.10.003</ArticleId><ArticleId IdType="pubmed">21051293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun. Rev. 2016;15:38&#x2013;49. doi: 10.1016/j.autrev.2015.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.08.010</ArticleId><ArticleId IdType="pubmed">26318215</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Sun L. Stem cell therapy in lupus. Rheumatol. Immunol. Res. 2022;3:61&#x2013;68. doi: 10.2478/rir-2022-0011.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rir-2022-0011</ArticleId><ArticleId IdType="pmc">PMC9524813</ArticleId><ArticleId IdType="pubmed">36465325</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721&#x2013;731. doi: 10.1016/S0140-6736(10)61354-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101:403&#x2013;413. doi: 10.1016/j.kint.2021.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.08.027</ArticleId><ArticleId IdType="pubmed">34560137</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet397, 2070&#x2013;2080 (2021). Erratum in: Lancet397, 2048 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatham WW, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study. Arthritis Rheumatol. 2021;73:816&#x2013;825. doi: 10.1002/art.41598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41598</ArticleId><ArticleId IdType="pmc">PMC8252065</ArticleId><ArticleId IdType="pubmed">33225631</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Mendez LM, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin. J. Am. Soc. Nephrol. 2018;13:1502&#x2013;1509. doi: 10.2215/CJN.01070118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01070118</ArticleId><ArticleId IdType="pmc">PMC6218830</ArticleId><ArticleId IdType="pubmed">30089664</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment&#x2014;clinical response compared to literature and immunological re-assessment. Autoimmun. Rev. 2015;14:1123&#x2013;1130. doi: 10.1016/j.autrev.2015.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.07.017</ArticleId><ArticleId IdType="pubmed">26244817</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, Sciascia S, Fenoglio R, Rossi D. A new challenge for lupus nephritis management: induction therapy without immunosuppressive maintenance regimen. Autoimmun. Rev. 2021;20:10284. doi: 10.1016/j.autrev.2021.102844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102844</ArticleId><ArticleId IdType="pubmed">33971336</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, et al. A prospective study on long-term clinical outcomes of patients with lupus nephritis treated with an intensified B-cell depletion protocol without maintenance therapy. Kidney Int. Rep. 2021;6:1081&#x2013;1087. doi: 10.1016/j.ekir.2021.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2021.01.027</ArticleId><ArticleId IdType="pmc">PMC8071649</ArticleId><ArticleId IdType="pubmed">33912758</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 2022;81:100&#x2013;107. doi: 10.1136/annrheumdis-2021-220920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId><ArticleId IdType="pmc">PMC8762029</ArticleId><ArticleId IdType="pubmed">34615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 2020;383:1149&#x2013;1155. doi: 10.1056/NEJMoa2023325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023325</ArticleId><ArticleId IdType="pubmed">32937047</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Rovin BH. Expert perspective: an approach to refractory lupus nephritis. Arthritis Rheumatol. 2022;74:915&#x2013;926. doi: 10.1002/art.42092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42092</ArticleId><ArticleId IdType="pmc">PMC9156543</ArticleId><ArticleId IdType="pubmed">35166048</ArticleId></ArticleIdList></Reference><Reference><Citation>Yo JH, Barbour TD, Nicholls K. Management of refractory lupus nephritis: challenges and solutions. Open Access Rheumatol. 2019;11:179&#x2013;188. doi: 10.2147/OARRR.S166303.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S166303</ArticleId><ArticleId IdType="pmc">PMC6636187</ArticleId><ArticleId IdType="pubmed">31372070</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, et al. CD38 and anti-CD38 monoclonal antibodies in AL amyloidosis: targeting plasma cells and beyond. Int. J. Mol. Sci. 2020;21:4129. doi: 10.3390/ijms21114129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21114129</ArticleId><ArticleId IdType="pmc">PMC7312896</ArticleId><ArticleId IdType="pubmed">32531894</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns M, et al. Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE. Int. J. Mol. Sci. 2021;22:2424. doi: 10.3390/ijms22052424.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052424</ArticleId><ArticleId IdType="pmc">PMC7957821</ArticleId><ArticleId IdType="pubmed">33670902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett L, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003;197:711&#x2013;723. doi: 10.1084/jem.20021553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021553</ArticleId><ArticleId IdType="pmc">PMC2193846</ArticleId><ArticleId IdType="pubmed">12642603</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA. 2003;100:2610&#x2013;2615. doi: 10.1073/pnas.0337679100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36:481&#x2013;490. doi: 10.1080/08916930310001625952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930310001625952</ArticleId><ArticleId IdType="pubmed">14984025</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci. Med. 2019;6:e000270. doi: 10.1136/lupus-2018-000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar-Camarena DC, Palafox-S&#xe1;nchez CA, Cruz A, Mar&#xed;n-Rosales M, Mu&#xf1;oz-Valle JF. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. Sci. Rep. 2020;10:6236. doi: 10.1038/s41598-020-63390-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-63390-0</ArticleId><ArticleId IdType="pmc">PMC7148319</ArticleId><ArticleId IdType="pubmed">32277232</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva M, Vieira P, O&#x2019;Garra A. Biology and therapeutic potential of interleukin-10. J. Exp. Med. 2020;217:e20190418. doi: 10.1084/jem.20190418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190418</ArticleId><ArticleId IdType="pmc">PMC7037253</ArticleId><ArticleId IdType="pubmed">31611251</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid. Redox Signal. 2013;18:2352&#x2013;2363. doi: 10.1089/ars.2012.4834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4834</ArticleId><ArticleId IdType="pmc">PMC3638564</ArticleId><ArticleId IdType="pubmed">22900885</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo A, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2016;375:754&#x2013;766. doi: 10.1056/NEJMoa1606038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606038</ArticleId><ArticleId IdType="pubmed">27557302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambello R, Baril&#xe0; G, Manni S, Piazza F, Semenzato G. NK cells and CD38: implication for (immuno)therapy in plasma cell dyscrasias. Cells. 2020;9:768. doi: 10.3390/cells9030768.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9030768</ArticleId><ArticleId IdType="pmc">PMC7140687</ArticleId><ArticleId IdType="pubmed">32245149</ArticleId></ArticleIdList></Reference><Reference><Citation>de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 2011;186:1840&#x2013;1848. doi: 10.4049/jimmunol.1003032.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1003032</ArticleId><ArticleId IdType="pubmed">21187443</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521&#x2013;530. doi: 10.1111/j.1523-1755.2004.00443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>